MiR-34a functions as a tumor suppressor modulating EGFR in glioblastoma multiforme

Oncogene

Volumn 32, Issue 9, 2013, Pages 1155-1163

  Yin, D ^a,b   Ogawa, S ^c   Kawamata, N ^b   Leiter, A ^b   Ham, M ^b   Li, D ^d   Doan, N B ^b   Said, J W ^b   Black, K L ^b   Phillip Koeffler, H ^b,e,f  

^a SUN YAT SEN UNIVERSITY   (China)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF TOKYO   (Japan)

^d HARBOR UCLA MEDICAL CENTER   (United States)

^e NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^f NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

EGFR; genomic profiling; glioblastoma multiforme; miR 34a; YY 1

Indexed keywords

CD31 ANTIGEN; CYCLIN A1; CYCLIN B1; CYCLIN D1; CYCLIN D3; EPIDERMAL GROWTH FACTOR RECEPTOR; MICRORNA 34A; PROTEIN P21; PROTEIN P27; TRANSCRIPTION FACTOR YY1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CANCER CELL; CANCER INHIBITION; CELL CYCLE; CELL MIGRATION; CHROMOSOME 1P; CONTROLLED STUDY; DNA MICROARRAY; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL TIME; TUMOR XENOGRAFT;

ANIMALS; BRAIN NEOPLASMS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; GENE AMPLIFICATION; GENE DELETION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; GLIOBLASTOMA; HUMANS; MICE; MICE, NUDE; MICRORNAS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANSPLANTATION, HETEROLOGOUS; YY1 TRANSCRIPTION FACTOR;

MUS;

EID: 84874702790     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.132     Document Type: Article

References (45)

1. Duerr EM, Rollbrocker B, Hayashi Y, Peters N, Meyer-Puttlitz B, Louis DN et al. PTEN mutations in gliomas and glioneuronal tumors. Oncogene 1998; 16: 2259-2264.
2. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997; 275: 1943-1947.
3. Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 1997; 15: 356-362.
4. Schmidt EE, Ichimura K, Reifenberger G, Collins VP. CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res 1994; 54: 6321-6324.
5. Ueki K, Ono Y, Henson JW, Efird JT, von Deimling A, Louis DN. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res 1996; 56: 150-153.
6. Ghimenti C, Fiano V, Chiado-Piat L, Chio A, Cavalla P, Schiffer D. Deregulation of the p14ARF/Mdm2/p53 pathway and G1/S transition in two glioblastoma sets. J neuro oncol 2003; 61: 95-102.
7. Yin D, Ogawa S, Kawamata N, Tunici P, Finocchiaro G, Eoli M et al. High-resolution genomic copy number profiling of glioblastoma multiforme by single nucleotide polymorphism DNA microarray. Mol Cancer Res 2009; 7: 665-677.
8. Ljubimova JY, Khazenzon NM, Chen Z, Neyman YI, Turner L, Riedinger MS et al. Gene expression abnormalities in human glial tumors identified by gene array. Int J Oncol 2001; 18: 287-295.
9. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435: 834-838.
10. Welch C, Chen Y, Stallings RL. MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene 2007; 26: 5017-5022.
11. Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee KH et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell 2007; 26: 745-752.
12. He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y et al. A microRNA component of the p53 tumour suppressor network. Nature 2007; 447: 1130-1134.
13. Cole KA, Attiyeh EF, Mosse YP, Laquaglia MJ, Diskin SJ, Brodeur GM et al. A functional screen identifies miR-34a as a candidate neuroblastoma tumor suppressor gene. Mol Cancer Res 2008; 6: 735-742.
14. Tarasov V, Jung P, Verdoodt B, Lodygin D, Epanchintsev A, Menssen A et al. Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle 2007; 6: 1586-1593.
15. Bheda A, Creek KE, Pirisi L. Loss of p53 induces epidermal growth factor receptor promoter activity in normal human keratinocytes. Oncogene 2008; 27: 4315-4323.
16. Ragnarsson G, Eiriksdottir G, Johannsdottir JT, Jonasson JG, Egilsson V, Ingvarsson S. Loss of heterozygosity at chromosome 1p in different solid human tumours: association with survival. Br J Cancer 1999; 79: 1468-1474.
17. Solomon DA, Kim JS, Jenkins S, Ressom H, Huang M, Coppa N et al. Identification of p18 INK4c as a tumor suppressor gene in glioblastoma multiforme. Cancer Res 2008; 68: 2564-2569.
18. Barbashina V, Salazar P, Holland EC, Rosenblum MK, Ladanyi M. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene. Clin Cancer Res 2005; 11: 1119-1128.
19. Ichimura K, Vogazianou AP, Liu L, Pearson DM, Backlund LM, Plant K et al. 1p36 is a preferential target of chromosome 1 deletions in astrocytic tumours and homozygously deleted in a subset of glioblastomas. Oncogene 2008; 27: 2097-2108.
20. Bagchi A, Papazoglu C, Wu Y, Capurso D, Brodt M, Francis D et al. CHD5 is a tumor suppressor at human 1p36. Cell 2007; 128: 459-475.
21. Dong Z, Pang JS, Ng MH, Poon WS, Zhou L, Ng HK. Identification of two contiguous minimally deleted regions on chromosome 1p36.31-p36.32 in oligodendroglial tumours. Br J Cancer 2004; 91: 1105-1111.
22. Feinberg-Gorenshtein G, Avigad S, Jeison M, Halevy-Berco G, Mardoukh J, Luria D et al. Reduced levels of miR-34a in neuroblastoma are not caused by mutations in the TP53 binding site. Genes Chromosomes Cancer 2009; 48: 539-543.
23. Wei JS, Song YK, Durinck S, Chen QR, Cheuk AT, Tsang P et al. The MYCN oncogene is a direct target of miR-34a. Oncogene 2008; 27: 5204-5213.
24. Zanette DL, Rivadavia F, Molfetta GA, Barbuzano FG, Proto-Siqueira R, Silva-Jr WA et al. miRNA expression profiles in chronic lymphocytic and acute lymphocytic leukemia. Braz J Med Biol Res 2007; 40: 1435-1440.
25. Yan D, Zhou X, Chen X, Hu DN, Dong XD, Wang J et al. MicroRNA-34a inhibits uveal melanoma cell proliferation and migration through downregulation of c-Met. Invest Ophthalmol Vis Sci 2009; 50: 1559-1565.
26. Tazawa H, Tsuchiya N, Izumiya M, Nakagama H. Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells. Proc Natl Acad Sci USA 2007; 104: 15472-15477.
27. Rokhlin OW, Scheinker VS, Taghiyev AF, Bumcrot D, Glover RA, Cohen MB. MicroRNA-34 mediates AR-dependent p53-induced apoptosis in prostate cancer. Cancer Biol Ther 2008; 7: 1288-1296.
28. Chen H, Wang N, Burmeister M, McInnis MG. MicroRNA expression changes in lymphoblastoid cell lines in response to lithium treatment. Int J Neuropsychopharmacol 2009; 12: 1-7.
29. Li N, Fu H, Tie Y, Hu Z, Kong W, Wu Y et al. miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells. Cancer Lett 2009; 275: 44-53.
30. Li Y, Guessous F, Zhang Y, Dipierro C, Kefas B, Johnson E et al. MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. Cancer Res 2009; 69: 7569-7576.
31. Guessous F, Zhang Y, Kofman A. Catania A, Li Y, Schiff D et al. microRNA-34a is tumor suppressive in brain tumors and glioma stem cells. Cell Cycle 9: 1031-1036.
32. Hagman Z, Larne O, Edsjo A, Bjartell A, Ehrnstrom RA, Ulmert D et al. miR-34c is down regulated in prostate cancer and exerts tumor suppressive functions. Int J Cancer 2010; 127: 2768-2776.
33. Lee CH, Subramanian S, Beck AH, Espinosa I, Senz J, Zhu SX et al. MicroRNA profiling of BRCA1/2 mutation-carrying and non-mutation-carrying high-grade serous carcinomas of ovary. PLoS One 2009; 4: e7314.
34. Raver-Shapira N, Marciano E, Meiri E, Spector Y, Rosenfeld N, Moskovits N et al. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell 2007; 26: 731-743.
35. Lodygin D, Tarasov V, Epanchintsev A, Berking C, Knyazeva T, Korner H et al. Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle 2008; 7: 2591-2600.
36. Sun F, Fu H, Liu Q, Tie Y, Zhu J, Xing R et al. Downregulation of CCND1 and CDK6 by miR-34a induces cell cycle arrest. FEBS Lett 2008; 582: 1564-1568.
37. Taylor BS, Barretina J, Socci ND, Decarolis P, Ladanyi M, Meyerson M et al. Functional copy-number alterations in cancer. PLoS One 2008; 3: e3179.
38. Chakravarti A, Delaney MA, Noll E, Black PM, Loeffler JS, Muzikansky A et al. Prognostic and pathologic significance of quantitative protein expression profiling in human gliomas. Clin Cancer Res 2001; 7: 2387-2395.
39. Kaller M, Liffers ST, Oeljeklaus S, Kuhlmann K, Roh S, Hoffmann R et al. Genomewide characterization of miR-34a induced changes in protein and mRNA expression by a combined pulsed SILAC and micro-array analysis. Mol Cell Proteomics 2011; 10: 462-478.
40. Chen QR, Yu LR, Tsang P, Wei JS, Song YK, Cheuk A et al. Systematic proteome analysis identifies transcription factor YY1 as a direct target of miR-34a. J Proteome Res 2011; 10: 479-487.
41. Nannya Y, Sanada M, Nakazaki K, Hosoya N, Wang L, Hangaishi A et al. A robust algorithm for copy number detection using high-density oligonucleotide single nucleotide polymorphism genotyping arrays. Cancer Res 2005; 65: 6071-6079.
42. Yamamoto G, Nannya Y, Kato M, Sanada M, Levine RL, Kawamata N et al. Highly sensitive method for genomewide detection of allelic composition in nonpaired, primary tumor specimens by use of affymetrix single-nucleotide- polymorphism genotyping microarrays. Am J Hum Genet 2007; 81: 114-126.
43. Hemann MT, Fridman JS, Zilfou JT, Hernando E, Paddison PJ, Cordon-Cardo C et al. An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo. Nat Genet 2003; 33: 396-400.
44. Yin D, Chen W, O'Kelly J, Lu D, Ham M, Doan NB et al. Connective tissue growth factor associated with oncogenic activities and drug resistance in glioblastoma multiforme. Int J Cancer 2010; 127: 2257-2267.
45. Kefas B, Godlewski J, Comeau L, Li Y, Abounader R, Hawkinson M et al. microRNA-inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. Cancer Res 2008; 68: 3566-3572.